Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
84.64 USD -1.44% Intraday chart for BioNTech SE -8.08% -19.80%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial MT
Sector Update: Health Care Stocks Ease in Afternoon Trading MT
Top Midday Stories: Nvidia Gets SCOTUS Review of Crypto Sales Lawsuit; Apple Supplier Develops Material for Solid-State Batteries; OpenAI Reportedly Launches Medical AI Tool; Walt Disney's 'Inside Out 2' Sets Biggest Opening of 2024; IQVentures to Acquire Aaron's MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading MT
BioNTech Says US FDA Placed Partial Clinical Hold on Cancer Drug Trial MT
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug RE
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
Indonesia ramps up fight against tuberculosis amid concerns on economic impact RE
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say RE
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading MT
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab CI
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower MT
BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa MT
BioNTech gets $145 mln funding for African vaccine plants RE
BioNTech and CEPI Expand Partnership to Strengthen Africa?s mRNA Vaccine Ecosystem CI
BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants RE
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
BioNTech Collaborating with MediLink to Develop More Potential Antibody-Drug Conjugate, Immunotherapy Treatments MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower MT
BIONTECH : Deutsche Bank remains Neutral ZD
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
Medigene, BioNTech Extend Cancer Immunotherapy Partnership MT
Chart BioNTech SE
More charts
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
80.14 EUR
Average target price
103.5 EUR
Spread / Average Target
+29.11%
Consensus
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. News BioNTech SE
  5. Sector Update: Health Care Stocks Advance in Monday Afternoon Trading